Skip to content

Clinical effect of point application combined with desomumab in the treatment of postmenopausal osteoporosis

Clinical effect of acupoint application combined with desomumab in the treatment of postmenopausal osteoporosis study

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2200006016
Enrollment
Unknown
Registered
2022-05-16
Start date
2022-05-06
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postmenopausal osteoporosis

Interventions

Intervention group:Acupoint sticking + desomumab + Basic treatment
Control group:Desomumab + Basic treatment

Sponsors

The Second Affiliated Hospital of Zhejiang Chinese Medicine University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
50 Years to 80 Years

Inclusion criteria

Inclusion criteria: ? Through bone mineral density examination, according to the lumbar bone mineral density (BMD) measured by DXA, lumbar T=-2.5SD. ? The patient has normal menopause and has been menopausal for more than 5 years; ? Female patients aged between 50 and 80 years old; ? Those who are willing to be subjects, can guarantee to complete the treatment course and sign informed consent.

Exclusion criteria

Exclusion criteria: ? Does not meet the diagnostic criteria of osteoporosis; ? Diabetes mellitus, thyroid or parathyroid functional changes, osteomalacia, rheumatoid arthritis, multiple myeloma, bone tumors, Paget's disease, osteogenesis imperfection and other diseases that seriously affect bone metabolism; ? Uterus and ovaries removed; (4) those who have used hormones, calcitonin or other drugs affecting bone metabolism within six months; ? Patients with serious cardiovascular and cerebrovascular diseases or liver and kidney failure; ? Other diseases and factors that can cause secondary osteoporosis. Patients with a history of severe skin allergy or skin sensitivity

Design outcomes

Primary

MeasureTime frame
Bone mineral density;

Secondary

MeasureTime frame
TCM clinical symptom score;Bone metabolic index;

Countries

China

Contacts

Public Contactshixiaolin

The Second Affiliated Hospital of Zhejiang Chinese Medicine University

1578379054@qq.com15279137993

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026